Please use a PC Browser to access Register-Tadawul
Get It
FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv For Muscle Invasive Bladder Cancer
Merck & Co., Inc. MRK | 121.41 121.41 | -1.95% 0.00% Pre |
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer
